NASDAQ:ARCT

Arcturus Therapeutics Stock Forecast, Price & News

$53.78
+1.49 (+2.85 %)
(As of 09/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$51.40
$53.96
50-Day Range
$27.88
$58.25
52-Week Range
$24.87
$129.71
Volume283,481 shs
Average Volume927,643 shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.91
30 days | 90 days | 365 days | Advanced Chart
Receive ARCT News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Arcturus Therapeutics logo

About Arcturus Therapeutics

Arcturus Therapeutics Holdings, Inc. is a clinical-stage mRNA medicines and vaccines company, which focuses on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.27 out of 5 stars

Medical Sector

285th out of 1,352 stocks

Pharmaceutical Preparations Industry

138th out of 665 stocks

Analyst Opinion: 2.9Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Arcturus Therapeutics (NASDAQ:ARCT) Frequently Asked Questions

Is Arcturus Therapeutics a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 6 sell ratings, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Arcturus Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares.
View analyst ratings for Arcturus Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Arcturus Therapeutics?

Wall Street analysts have given Arcturus Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arcturus Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Arcturus Therapeutics?

Arcturus Therapeutics saw a drop in short interest during the month of August. As of August 13th, there was short interest totaling 2,260,000 shares, a drop of 38.6% from the July 29th total of 3,680,000 shares. Based on an average daily volume of 863,700 shares, the days-to-cover ratio is presently 2.6 days. Currently, 10.5% of the shares of the company are short sold.
View Arcturus Therapeutics' Short Interest
.

When is Arcturus Therapeutics' next earnings date?

Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Arcturus Therapeutics
.

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its earnings results on Sunday, August, 8th. The biotechnology company reported ($2.07) EPS for the quarter, missing analysts' consensus estimates of ($1.99) by $0.08. Arcturus Therapeutics had a negative net margin of 1,874.18% and a negative trailing twelve-month return on equity of 48.39%.
View Arcturus Therapeutics' earnings history
.

How has Arcturus Therapeutics' stock price been impacted by Coronavirus?

Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARCT shares have increased by 310.8% and is now trading at $53.78.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ARCT?

10 analysts have issued 1-year price objectives for Arcturus Therapeutics' shares. Their forecasts range from $23.00 to $133.00. On average, they expect Arcturus Therapeutics' stock price to reach $63.55 in the next year. This suggests a possible upside of 18.2% from the stock's current price.
View analysts' price targets for Arcturus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Arcturus Therapeutics' key executives?

Arcturus Therapeutics' management team includes the following people:
  • Joseph E. Payne, President, Chief Executive Officer & Director
  • Padmanabh Chivukula, Secretary, Chief Operating & Scientific Officer
  • Andrew H. Sassine, Chief Financial Officer & Director
  • Steven G. Hughes, Chief Medical Officer
  • Keith Kummerfeld, Vice President-Finance & Controller

What is Joe Payne's approval rating as Arcturus Therapeutics' CEO?

9 employees have rated Arcturus Therapeutics CEO Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among Arcturus Therapeutics' employees.

Who are some of Arcturus Therapeutics' key competitors?

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and (SNY).

What is Arcturus Therapeutics' stock symbol?

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Who are Arcturus Therapeutics' major shareholders?

Arcturus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Federated Hermes Inc. (11.50%), ARK Investment Management LLC (10.96%), State Street Corp (6.67%), BlackRock Inc. (6.47%), Sumitomo Mitsui Trust Holdings Inc. (4.62%) and Nikko Asset Management Americas Inc. (4.62%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Pad Chivukula and Ultragenyx Pharmaceutical Inc.
View institutional ownership trends for Arcturus Therapeutics
.

Which institutional investors are selling Arcturus Therapeutics stock?

ARCT stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Federated Hermes Inc., Millennium Management LLC, Goldman Sachs Group Inc., Renaissance Technologies LLC, Price T Rowe Associates Inc. MD, Group One Trading L.P., and BlackRock Inc.. Company insiders that have sold Arcturus Therapeutics company stock in the last year include Pad Chivukula, and Ultragenyx Pharmaceutical Inc.
View insider buying and selling activity for Arcturus Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Arcturus Therapeutics stock?

ARCT stock was purchased by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., State Street Corp, Morgan Stanley, Morgan Stanley, Nuveen Asset Management LLC, Rafferty Asset Management LLC, and Monashee Investment Management LLC. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, and Keith C Kummerfeld.
View insider buying and selling activity for Arcturus Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcturus Therapeutics' stock price today?

One share of ARCT stock can currently be purchased for approximately $53.78.

How much money does Arcturus Therapeutics make?

Arcturus Therapeutics has a market capitalization of $1.42 billion and generates $9.54 million in revenue each year. The biotechnology company earns $-72,150,000.00 in net income (profit) each year or ($3.55) on an earnings per share basis.

How many employees does Arcturus Therapeutics have?

Arcturus Therapeutics employs 118 workers across the globe.

What is Arcturus Therapeutics' official website?

The official website for Arcturus Therapeutics is www.arcturusrx.com.

Where are Arcturus Therapeutics' headquarters?

Arcturus Therapeutics is headquartered at 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121.

How can I contact Arcturus Therapeutics?

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 900-2660 or via email at [email protected]


This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.